Brain Tumours

A Phase 1 Study of AZD6244 in Children with Recurrent or Refractory Low Grade Gliomas: A Pediatric Brain Tumor Consortium Report . Toxicity • Dose limiting toxicities were headache, rash, mucositis, and elevation of amylase and lipase • Maximum tolerated dosage = 25 mg/m2/dose • At dose levels above 25mg/m2/dose, toxicities resulted in treatment discontinuation rate of 36 %